Mẫu số 01-B

CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY

Số: 802 /CV-DHT

CỘNG HÒA XÃ HỘI CHỦ NGHĨA VIỆT NAM

Độc lập - Tự do - Hạnh phúc

Hà Nội, ngày 28 tháng 10 năm 2026

CÔNG BỐ THÔNG TIN ĐỊNH KỲ BÁO CÁO TÀI CHÍNH

Kính gửi: Sở Giao dịch Chứng khoán Hà Nội

Thực hiện quy định tại Khoản 3 Điều 14 Thông tư số 96/2020/TT-BTC ngày 16/11/2020 của Bộ Tài chính hướng dẫn công bố thông tin trên thị trường chứng khoán, CTCP Dược phẩm Hà Tây thực hiện công bố thông tin báo cáo tài chính (BCTC) quý 3/năm 2026 với Sở Giao dịch Chứng khoán Hà Nội như sau:

1. Tên tổ chức: CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY

- Mã chứng khoán: DHT
- Địa chỉ: Số 10A phố Quang Trung, phường Hà Đông, TP. Hà Nội
- Điện thoại liên hệ/Tel: 0433 501 117 Fax:
- Email: duochatay@gmail.com
- Website: https://www.hataphar.com.vn

2. Nội dung thông tin công bố:

- BCTC quý 3/năm 2026

[X] BCTC riêng (TCNY không có công ty con và đơn vị kế toán cấp trên có đơn vị trực thuộc);

[X] BCTC hợp nhất (TCNY có công ty con);

[ ] BCTC tổng hợp (TCNY có đơn vị kế toán trực thuộc tổ chức bộ máy kề toán riêng).

- Các trường hợp thuộc diện phải giải trình nguyên nhân:

+ Tổ chức kiểm toán đưa ra ý kiến không phải là ý kiến chấp nhận toàn phần đối với BCTC (đối với BCTC được soát xét/được kiểm toán):

[ ] Có [X] Không

Văn bản giải trình trong trường hợp tích có:

[ ] Có [ ] Không

+ Lợi nhuận sau thuế trong kỳ báo cáo có sự chênh lệch trước và sau kiểm toán từ 5% trở lên, chuyển từ lỗ sang lãi hoặc ngược lại (đối với BCTC được kiểm toán năm 2026):

[ ] Có [X] Không

Văn bản giải trình trong trường hợp tích có:

☐ Có ☐ Không

+ Lợi nhuận sau thế thu nhập doanh nghiệp tại báo cáo kết quả kinh doanh của kỳ báo cáo thay đổi từ 10% trở lên so với báo cáo cùng kỳ năm trước:

☒ Có ☐ Không

Văn bản giải trình trong trường hợp tích có:

☒ Có ☐ Không

+ Lợi nhuận sau thuế trong kỳ báo cáo bị lỗ, chuyển từ lãi ở báo cáo cùng kỳ năm trước sang lỗ ở kỳ này hoặc ngược lại:

☐ Có ☒ Không

Văn bản giải trình trong trường hợp tích có:

☐ Có ☐ Không

Thông tin này đã được công bố trên trang thông tin điện tử của công ty vào ngày: 29/10/2026 tại đường dẫn: https://www.hataphar.com.vn/thong-tin-codong.html3.

3. Báo cáo về các giao dịch có giá trị từ 35% tổng tài sản trở lên trong năm 2026: Không có

Trường hợp TCNY có giao dịch đề nghị báo cáo đầy đủ các nội dung sau:

- Nội dung giao dịch:
- Tỷ trọng giá trị giao dịch/tổng giá trị tài sản của doanh nghiệp (%) (*căn cứ trên báo cáo tài chính năm gần nhất*):
- Ngày hoàn thành giao dịch

Chúng tôi xin cam kết các thông tin công bố trên đây là đúng sự thật và hoàn toàn chịu trách nhiệm trước pháp luật về nội dung các thông tin công bố.

Đại diện tổ chức
Người đại diện theo pháp luật/Người UQCBTT
(Ký, ghi rõ họ tên, chức vụ, đóng dấu)

Tài liệu đính kèm:
- BCTC riêng Quý 3.2026
- BCTC HN Quý 3.2026
- Văn bản giải trình

CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY

TỔNG GIÁM ĐỐC
OSAMU YOMOGIDA

HATAPHAR
CÔNG TY CP DƯỢC PHẨM HÀ TÂY

No.: 804 /CV-BCTC-DHT

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

Hanoi, October 28, 2026

To: The State Securities Commission of Viet Nam
Hanoi Stock Exchange

Company name: Ha Tay Pharmaceutical Joint Stock Company
Stock Code: DHT
Head office: 10A Quang Trung – Ha Dong Ward – Hanoi City
Phone: 0433 501 117 – Fax: 0433 829 054
Information disclosure officer: Mrs. Pham Minh Thu – Deputy Manager of Legal and Communications Department.

In the separate financial statements for Q3 2026, the business results of Hatay Pharmaceutical Joint Stock Company are as follows:

The total profit after tax in Q3 2026 was VND 6.088.052.695, compared to VND 12.009.217.647 in Q3 2025 — a decrease of VND 5.921.164.952, equivalent to 49.31%. This was mainly due to:

- Gross profit in Q3 2026 was VND 44,082,106,018, compared with VND 43,297,567,643 in Q3 2025, an increase of VND 784,538,375.
- Financial income in Q3 2026 amounted to VND 3,226,139,139, compared with VND 10,554,757,527 in Q3 2025, a decrease of VND 7,328,618,388, equivalent to a decrease of 69.43%. The decline in financial income adversely affected the Company's profit for the period.
- Selling expenses and general and administrative expenses in Q3 2026 amounted to VND 47,709,692,009, compared with VND 40,646,889,607 in Q3 2025, an increase of VND 7,062,802,402, equivalent to an increase of 17.38%. The increase in selling expenses and general and administrative expenses affected the Company's profit for the period.

We hereby report to the State Securities Commission of Vietnam and the Hanoi Stock Exchange for your information.

Recipient:
- As above
- Archive: Office files

HA TAY PHARMACEUTICAL JOINT STOCK COMPANY
General Director

M.S.D.N: 0500391406 C.T.C.P. CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY P. HÀ ĐÔNG - TP. HÀ NỘI

Osamu Yomogida

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

INTERIM SEPARATE FINANCIAL STATEMENTS

For the period from 01/07/2026 to 30/09/2026

HANOI, OCTOBER 2026

Form B 01a - DN

INTERIM SEPARATE STATEMENT OF FINANCIAL POSITION

As at September 30, 2026

Unit: VND

	ASSETS	Codes	Notes	30/09/2026	01/01/2026
A -	**CURRENT ASSET**	**100**		**667,127,776,007**	**852,330,784,028**
I.	**Cash and cash equivalents**	**110**		**95,674,826,115**	**62,204,146,573**
1.	Cash	111	I.1.	45,674,826,115	62,204,146,573
2.	Cash equivalents	112		50,000,000,000	-
II.	**Short-term financial investments**	**120**		**100,286,027,330**	**153,045,424,635**
1.	Short-term held-to-maturity investments	124	I.2.	100,286,027,330	153,045,424,635
III.	**Short-term receivables**	**130**		**165,745,056,986**	**146,744,235,162**
1.	Short-term trade receivables	131	I.3.	136,498,823,267	117,809,555,476
2.	Short-term advances to suppliers	132	I.4.	32,774,487,016	32,697,898,240
3.	Other short-term receivables	135	I.5.	284,353,661	117,926,940
4.	Provision for short-term doubtful debts	136		(3,812,606,958)	(3,881,145,494)
IV.	**Inventories**	**140**	**I.7.**	**303,724,170,717**	**490,336,977,658**
1.	Inventories	141		303,724,170,717	490,336,977,658
2.	Provision for devaluation of inventories	142		-	-
V.	**Short-term biological assets**	**150**		-	-
VI.	**Other current assets**	**160**		**1,697,694,859**	-
1.	Value added tax deductibles	162		1,697,694,859	-
B -	**NON-CURRENT ASSETS**	**200**		**997,478,375,292**	**1,021,303,483,731**
I.	**Other long-term receivables**	**210**		**6,407,042,500**	**6,407,042,500**
1	Other long-term receivables	216	I.5.	6,407,042,500	6,407,042,500
II.	**Fixed assets**	**220**		**875,887,656,428**	**159,786,858,109**
1.	Tangible fixed assets	221	I.9.	874,510,996,428	158,410,198,109
	- Historical cost	*222*		*1,134,070,892,507*	*398,075,756,774*
	- Accumulated depreciation	*223*		*(259,559,896,079)*	*(239,665,558,665)*
2.	Intangible fixed assets	227	I.8.	1,376,660,000	1,376,660,000
	- Historical cost	*228*		*2,026,660,000*	*2,026,660,000*
	- Accumulated amortization	*229*		*(650,000,000)*	*(650,000,000)*
III.	**Long-term biological assets**	**230**		-	-
IV.	**Investment property**	**240**		-	-
V.	**Long-term assets in progress**	**250**		**1,700,433,384**	**823,583,883,872**
1.	Construction in progress	252	I.10.	1,700,433,384	823,583,883,872
VI.	**Long-term financial investments**	**260**	**I.2.**	**25,893,525,000**	**25,893,525,000**
1.	Investment into subsidiaries	261		22,743,525,000	22,743,525,000
2.	Investments into joint-venture, associates	262		3,150,000,000	3,150,000,000
VII.	**Other non-current assets**	**270**		**87,589,717,980**	**5,632,174,250**
1.	Long-term deferred expenses	271	I.11.	87,589,717,980	5,632,174,250
	TOTAL ASSETS (280 = 100 + 200)	**280**		**1,664,606,151,299**	**1,873,634,267,759**

Form B 01a - DN

INTERIM SEPARATE STATEMENT OF FINANCIAL POSITION

As at September 30, 2026
(continued)

Unit: VND

	RESOURCES	Codes	Notes	30/09/2026	01/01/2026
					-
C -	**LIABILITY**	**300**		**568,437,709,948**	**803,590,904,233**
I.	**Current liabilities**	**310**		**482,173,262,401**	**717,185,556,686**
1.	Short-term trade payables	311	I.12.	236,186,426,720	256,117,722,179
2.	Short-term advances from customers	312	I.13.	59,263,375,163	177,873,939,986
3	Taxes and payables to the State Treasury	314	I.14.	2,595,858,839	4,293,778,212
4	Payables to employees	315		19,895,450,863	25,671,261,962
5	Short-term accrued expenses	316	I.15.	1,298,653,892	111,756,803
6	Short-term deferred revenue	319	I.16.	1,228,062,420	575,370,229
7	Other short-term payables	320	I.17.	1,133,800,665	191,526,944
8	Short-term loans and obligations under finance lease	321	I.18.	160,565,050,276	249,995,403,408
9	Welfare and bonus fund	323		6,583,563	2,354,796,963
II.	**Non-current liabilities**	**330**		**86,264,447,547**	**86,405,347,547**
1.	Other long-term payables	338	I.17.	3,196,200,000	3,337,100,000
2.	Long-term loans and obligations under finance lease	339	I.18.	83,068,247,547	83,068,247,547
D -	**OWNER'S EQUITY**	**400**	**I.19.**	**1,096,168,441,351**	**1,070,043,363,526**
1.	Owner's contributed capital	411		905,755,510,000	905,755,510,000
-	*Ordinary shares carrying voting rights*	*411a*		*905,755,510,000*	*905,755,510,000*
2.	Share premium	412		36,282,220,000	36,282,220,000
3.	Other owner's capital	414		-	24,375,893,101
4.	Treasury shares	415		(15,130,000)	(15,130,000)
5.	Investment and development fund	418		8,963,148,976	8,963,148,976
6.	Retained earnings	420		145,182,692,375	94,681,721,449
-	*Retained earnings accumulated to the prior year end*	*420a*		*119,057,614,550*	*42,236,134,228*
-	*Retained earnings of this period*	*420b*		*26,125,077,825*	*52,445,587,221*
	TOTAL RESOURCES (440=300 + 400)	**440**		**1,664,606,151,299**	**1,873,634,267,759**

Approved, October 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by	Chief Accountant	General Director
Nguyen Hai Trieu	Dinh Nam Ha	Osamu Yomogida

Form B 02a - DN

INTERIM SEPARATE INCOME STATEMENT

For the period from 01/07/2026 to 30/09/2026

Unit: VND

	Codes	Notes	Quarter III		Accumulated from the beginning of the year	
			FY 2026	FY 2025	FY 2026	FY 2025
1 Gross revenue from goods sold and services rende	**01**	**II.1.**	**517.278.293.726**	**603.554.251.928**	**1.618.113.986.381**	**1.619.157.642.556**
2 **Revenue deductions**	02	II.2.	283.302.244	15.697.260	332.278.006	15.697.260
3 Net revenue from goods sold and services rendere (10=01-02)	**10**	**II.3.**	**516.994.991.482**	**603.538.554.668**	**1.617.781.708.375**	**1.619.141.945.296**
4 Cost of goods sold	11	II.4.	472.912.885.464	560.240.987.025	1.489.057.872.177	1.475.547.788.769
5 Gross profit from goods sold and services rendere (20 =10-11)	**20**		**44.082.106.018**	**43.297.567.643**	**128.723.836.198**	**143.594.156.527**
6 Gain/Loss from the sale, liquidation of investment properties	**21**		-	-	-	-
7 Financial income	22	II.5.	3.226.139.139	10.554.757.527	14.453.641.834	23.472.675.789
8 Financial expenses	23	II.6.	5.296.199.530	3.673.716.326	11.823.440.180	16.919.529.390
- In which: Borrowing costs	*24*		*5.064.226.124*	*3.170.986.255*	*10.822.889.317*	*10.298.212.042*
9 Selling expenses	25	II.9.	7.193.907.168	6.580.717.254	27.825.679.065	20.520.283.386
10 General and administration expenses	26	II.9.	40.515.784.841	34.066.172.353	89.926.744.397	91.480.279.258
11 Operating profit (30=20+21+22-(23+25+26))	**30**		**(5.697.646.382)**	**9.531.719.237**	**13.601.614.390**	**38.146.740.282**
12 Other income	31	II.7.	15.858.648.657	4.181.387.197	22.586.763.137	11.625.895.587
13 Other expenses	32	II.8	639.367.742	-	1.414.473.468	629.444.489
14 Profit from other activities (40 = 31 - 32)	**40**		**15.219.280.915**	**4.181.387.197**	**21.172.289.669**	**10.996.451.098**
15 Accounting profit before tax (50=30+40)	**50**		**9.521.634.533**	**13.713.106.434**	**34.773.904.059**	**49.143.191.380**
16 Current corporate income tax expenses	51	II.10.	3.433.581.838	1.703.888.787	8.648.826.234	8.520.986.520

17	Deferred corporate income tax expenses	52	-	-	-	-
18	**Net profit after corporate income tax (60=50-51-52)**	**60**	**6.088.052.695**	**12.009.217.647**	**26.125.077.825**	**40.622.204.860**

Approved, October 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by	Chief Accountant	General Director
Nguyen Hai Trieu	Đinh Nam Ha	Osamu Yomogida

Form B 03a - DN

INTERIM SEPARATE CASH FLOW STATEMENT

(Under indirect method)

For the period from 01/07/2026 to 30/09/2026

Unit: VND

	ITEMS	Codes	Notes	Quarter III		Accumulated from the beginning of the year	
				FY 2026	FY 2025	FY 2026	FY 2025
I.	**Cash flows from operating activities**						
1.	***Profit before tax***	***01***		**9,521,634,533**	***13,713,106,434***	***34,773,904,059***	***49,143,191,380***
2.	***Adjustments for***						
	Depreciation of fixed assets and investment properties	02		15,611,207,750	3,130,987,242	26,761,754,219	14,004,942,941
	Provisions	03		-		(68,538,536)	212,849,489
	Foreign exchange gains and losses arising from translating foreign currency items	04		907,596,535	(4,951,541,341)	(79,884,639)	348,185,862
				-			
	Gains and losses from investing activities	05		(518,782,869)	(7,041,754,884)	(4,070,496,451)	(12,114,730,145)
	Borrowing costs	06		5,064,226,124	3,170,986,255	10,822,889,317	10,298,212,042
3.	***Operating profit before movements in working capital***	***08***		***30,585,882,073***	***8,021,783,706***	***68,139,627,969***	***61,892,651,569***
	Increase, decrease in receivables	09		(23,064,671,536)	39,630,380,671	(33,309,490,813)	50,533,939,583
	Increase, decrease in inventories	10		50,897,569,228	(18,345,514,560)	186,612,806,941	(45,146,686,413)
	Increase, decrease in payables (Excluding interest payable and corporate income tax payable)	11		(263,737,272)	(3,741,372,416)	(129,073,904,029)	94,759,911,630
				-			
	Increase, decrease in deferred expenses	12		(5,783,523,911)	534,863,987	(7,381,832,111)	794,120,404
	Borrowing costs paid	14		(5,035,656,375)	(4,167,072,120)	(10,809,786,406)	(11,340,310,432)
	Corporate income tax paid	15		(4,511,768,097)	(2,714,525,322)	(10,586,737,553)	(11,451,312,905)
	Other cash outflows	17		(78,800,000)	(10,600,000)	(2,348,213,400)	(189,562,877)
	Net cash flows from operating activities	***20***		***42,745,294,110***	***19,207,943,946***	***61,242,470,598***	***139,852,750,559***
II.	**Cash flows from investing activities**						
1.	Acquisition and construction of fixed assets and other non-	21		(3,655,765,901)	4,014,006,182	(7,930,728,985)	(35,517,931,338)
2.	Proceeds from sale, disposal of fixed assets and other non-	22		10,000,000,000		10,000,000,000	100,000,000
3.	Cash outflows for lending, buying debt instruments of other	23		(90,000,000,000)	(350,000,000,000)	(210,000,000,000)	(410,000,000,000)
4.	Cash recovered from lending, selling debt instruments of	24		92,759,397,305	260,000,000,000	262,759,397,305	350,000,000,000
5.	Interest earned, dividends and profits received	27		2,782,289,739	7,672,056,249	6,829,893,756	12,947,058,929
	Net cash flow from investment activities	***30***		***11,885,921,143***	***(78,313,937,569)***	***61,658,562,076***	***(82,470,872,409)***
III.	**Cash flow from financial activities**						

1.	Proceeds from borrowing	33		95.032.989.687	142.819.156.374	303.768.031.563	524.082.210.741
2.	Repayment of borrowing	34		(95.116.246.207)	(186.292.047.148)	(393.198.384.695)	(615.136.920.329)
	Net cash flow from financial activities	***40***		***(83.256.520)***	***(43.472.890.773)***	***(89.430.353.132)***	***(91.054.709.588)***
	Net cash flow in the period (50 = 20+30+40)	**50**		**54.547.958.733**	**(102.578.884.396)**	**33.470.679.542**	**(33.672.831.438)**
	Cash and cash equivalents at the beginning of the period	**60**		**41.136.446.368**	**138.239.257.205**	**62.204.146.573**	**69.332.546.815**
	Effect of changes in foreign exchange rates	61		(9.578.986)	(657.432)	-	-
	Cash and cash equivalents at the end of the period (70 = 50+60+61)	**70**	**I.01**	**95.674.826.115**	**35.659.715.377**	**95.674.826.115**	**35.659.715.377**

Approved, October 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by	Chief Accountant	General Director
Nguyen Hai Trieu	Dinh Nam Ha	Osamu Yomogida

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

I. Additional information of items presented in Interim Separate Statement of Financial Position

1. Cash and cash equivalents

	30/09/2026 VND	01/01/2026 VND
Cash	**45.674.826.115**	**62.204.146.573**
Cash on hand	***2.396.208.476***	***3.282.320.320***
Cash in bank	***43.278.617.639***	***58.921.826.253***
Cash in bank - VND	42.784.953.280	58.797.090.293
Other banks	*493.664.359*	*124.735.960*
Cash in bank - USD	483.090.044	113.685.066
Cash in bank - EUR	10.574.315	11.050.894
Cash equivalents	**50.000.000.000**	**-**
Total	**95.674.826.115**	**62.204.146.573**

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

2. Financial investments

a) Held-to-maturity investments

Unit: VND

	30/9/2026			01/01/2026		
	Carrying amount	**Recoverable amount**	**Provision amount**	**Carrying amount**	**Recoverable amount**	**Provision amount**
Short-term	**100.286.027.330**	**100.286.027.330**	**-**	**153.045.424.635**	**153.045.424.635**	**-**
Vietnam Joint Stock Commercial Bank for Industry and Trade - Thanh An Branch (i)	-	-	-	81.904.219.178	81.904.219.178	-
Vietnam Asia Commercial Joint Stock Bank - Ha Dong Branch (i)	60.286.027.330	60.286.027.330	-	30.546.356.141	30.546.356.141	-
Vietnam Technological and Commercial Joint Stock Bank - Dong Do Branch (i)	40.000.000.000	40.000.000.000	-	40.594.849.316	40.594.849.316	-
Total	**100.286.027.330**	**100.286.027.330**	**-**	**153.045.424.635**	**153.045.424.635**	**-**

(i) Time deposit contracts at commercial banks have interest rates that vary depending on the contract.

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

b) Capital contribution into other entities

	30/09/2026		01/01/2026	
	VND		VND	
	Cost	Provision	Cost	Provision
Investment into subsidiaries	***22,743,525,000***	-	***22,743,525,000***	-
Hatay Pharmaceutical and Medical Equipment JSC (i)	22,743,525,000	-	22,743,525,000	-
Investments into associates	***3,150,000,000***	-	***3,150,000,000***	-
Southern Hataphar Co., Ltd (ii)	700,000,000	-	700,000,000	-
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC (iii)	2,450,000,000	-	2,450,000,000	-
Total (*)	**25,893,525,000**	-	**25,893,525,000**	-

Summary of operations in subsidiaries, associates:

(i) According to the 12th amended Business Registration Certificate dated 29/7/2025, the Company invested in Hatay Pharmaceutical and Medical Equipment JSC with a value of VND 20,857,750,000, equivalent to 50.63% of the charter capital. At the end of the accounting period, the Company invested VND 20,857,750,000, equivalent to 50.63% of the charter capital.

(ii) According to the 13th amended Business Registration Certificate dated 18/11/2025, the Company invested in Southern Hataphar Co., Ltd with a value of VND 700,000,000, equivalent to 48.28% of the charter capital. At the end of the accounting period, the Company invested VND 700,000,000, equivalent to 48.28% of the charter capital.

(iii) According to the 5th amended Business Registration Certificate dated 07/04/2026, the Company invested in Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC with a value of VND 9,800,000,000, equivalent to 49% of the charter capital. At the end of the accounting period, the Company invested VND 9,800,000,000, equivalent to 49% of the charter capital.

Subsidiaries and associates are operating normally, with no major changes compared to prior period.

(*) As at September 30, 2026, all of the above investments undetermined fair value due to do not have market prices or insufficient information necessary to assess fair value. The fair value of these investments may differ from their book value.

3. Trade accounts receivable

	30/09/2026		01/01/2026	
	VND		VND	
	Amount	Provision	Amount	Provision
Short-term				
Ha Tay Pharmaceutical and Medical Equipment Joint Stock Company	10,394,008,862	-	13,747,403,367	-
Hataphar Healthcare Vietnam High-Tech Pharmaceutical Joint Stock	13,076,873,961	-	37,438,000,011	-
Dong Do Pharmaceutical Company Limited	18,136,825,054	-	-	-
Others	94,891,115,390	(3,100,934,958)	66,624,152,098	(3,169,473,494)
Total	**136,498,823,267**	**(3,100,934,958)**	**117,809,555,476**	**(3,169,473,494)**

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

4. Advances to suppliers

	30/09/2026 VND		01/01/2026 VND	
	Amount	Provision	Amount	Provision
Short-term				
Pharmametics products a division of max Biocare	9.408.141.816	-	2.573.704.006	-
Delta Pharma Ltd	1.516.328.883	-	7.846.059.364	-
Inbiotech l.t.d	646.177.815	-	6.997.520.425	-
Saifen Drugs Philippines Inc	3.559.213.500	-	2.840.549.628	-
Blis pharma distribution and Consultancy corp.	415.170.000	-	3.384.715.680	-
Others	17.229.455.002	(711.672.000)	9.055.349.137	(711.672.000)
Total	**32.774.487.016**	**(711.672.000)**	**32.697.898.240**	**(711.672.000)**

5. Other receivables

	30/09/2026 VND		01/01/2026 VND	
	Amount	Provision	Amount	Provision
a) Short-term	**284.353.661**	-	**117.926.940**	-
Other receivables	***33.496.071***	-	***26.950.629***	-
Advances	***250.857.590***	-	***90.976.311***	-
Nguyen Van Phuc	100.000.000	-	-	-
Others	150.857.590	-	90.976.311	-
b) Long-term	**6.407.042.500**	-	**6.407.042.500**	-
Mortgages, collaterals	***6.407.042.500***	-	***6.407.042.500***	-
Hoa Lac Hi-Tech Park Management Board (*)	6.407.042.500	-	6.407.042.500	-
Total	**6.691.396.161**	-	**6.524.969.440**	-

(*) The deposit for Hoa Lac High-Tech Park Management Board to ensure the implementation of the investment project "*Hataphar High-Tech Pharmaceutical Factory*" is agreed upon in the Investment Project Implementation Guarantee Deposit Agreement No. 06/TTKQ dated November 27, 2020.

6. Bad debts

	30/09/2026 VND		01/01/2026 VND	
	Cost	Recoverable value	Cost	Recoverable value
Total amount of receivables past due but impaired				
Trade accounts receivable	***3.460.368.948***	***359.433.990***	***3.539.882.618***	***370.409.124***
Thu Duc City Hospital	1.774.525.000	102.665.000	1.774.525.000	102.665.000
Others	1.685.843.948	256.768.990	1.765.357.618	267.744.124
Advances to suppliers	***711.672.000***	-	***711.672.000***	-
ERP Solutions JSC	711.672.000	-	711.672.000	-
Total	**4.172.040.948**	**359.433.990**	**4.251.554.618**	**370.409.124**

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

7. Inventories

	30/09/2026 VND		01/01/2026 VND	
	Cost	Provision	Cost	Provision
Goods in transit	63.775.740.695	-	127.357.336.205	-
Raw materials	72.545.341.576	-	70.055.789.195	-
Tools, instruments	51.413.477	-	56.353.924	-
Work in progress	13.038.839.086	-	9.735.832.625	-
Finished goods	55.942.375.232	-	23.437.595.070	-
Merchandise	98.370.460.651	-	259.694.070.639	-
Total	**303.724.170.717**	**-**	**490.336.977.658**	**-**

8. Increases, decreases of intangible fixed assets

Unit: VND

Items	Accounting software	Land use rights	Total
Historical cost			
Balance as at 01/01/2026	**650.000.000**	**1.376.660.000**	**2.026.660.000**
Balance as at 30/09/2026	**650.000.000**	**1.376.660.000**	**2.026.660.000**
Accumulated amortization			
Balance as at 01/01/2026	**650.000.000**	**-**	**650.000.000**
Balance as at 30/09/2026	**650.000.000**	**-**	**650.000.000**
Net book value			
As at 01/01/2026	**-**	**1.376.660.000**	**1.376.660.000**
As at 30/09/2026	**-**	**1.376.660.000**	**1.376.660.000**

Historical cost of fixed assets which has been fully depreciated as at 309/2026: VND 650,000,000 (As at 31/12/2025: VND 650,000,000).

(*) Details of intangible fixed assets with original cost equal to or greater than 10% of the total value of intangible fixed assets:

Name of fixed asset	30/09/2026 VND		
	Historical cost	Accumulated amortization	Net book value
Land Use Right at No. 62 Tran Van Giap, Ho Chi Minh City	1.376.660.000	-	1.376.660.000
Vietsun BA Business Accounting Software	650.000.000	650.000.000	-
Total	**2.026.660.000**	**650.000.000**	**1.376.660.000**

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

9. Increases, decreases of tangible fixed assets

Unit: VND

Items	Buildings and architectural objects	Machinery and equipment	Transportation means	Managerial equipment, tools	Other fixed assets	Total
Historical cost						
Balance as at 01/01/2026	**151.594.790.063**	**231.068.833.687**	**11.142.238.581**	**3.830.611.943**	**439.282.500**	**398.075.756.774**
Purchase in the period	-	418.851.000	-	-	-	**418.851.000**
Capital construction investment completed	414.760.846.073	317.814.954.679	66.903.781.902	718.695.935	-	**800.198.278.589**
Reclassification	-	(57.754.577.051)	-	-	-	**(57.754.577.051)**
Disposals	(3.188.910.590)	(3.632.791.929)	-	(45.714.286)	-	**(6.867.416.805)**
Balance as at 30/09/2026	**563.166.725.546**	**487.915.270.386**	**78.046.020.483**	**4.503.593.592**	**439.282.500**	**1.134.070.892.507**
Accumulated depreciation						
Balance as at 01/01/2026	**91.438.185.808**	**138.610.646.213**	**5.539.168.526**	**3.638.275.618**	**439.282.500**	**239.665.558.665**
Depreciation for the period	7.873.206.148	17.112.939.263	1.711.733.889	63.874.920	-	**26.761.754.219**
Disposals	(3.188.910.590)	(3.632.791.929)	-	(45.714.286)	-	**(6.867.416.805)**
Balance as at 30/09/2026	**96.122.481.366**	**152.090.793.547**	**7.250.902.415**	**3.656.436.252**	**439.282.500**	**259.559.896.079**
Net book value						
As at 01/01/2026	**60.156.604.255**	**92.458.187.474**	**5.603.070.055**	**192.336.325**	-	**158.410.198.109**
As at 30/09/2026	**467.044.244.180**	**335.824.476.839**	**70.795.118.068**	**847.157.340**	-	**874.510.996.428**

Historical cost of fixed assets which has been fully depreciated but still in use as at 30/09/2026: VND 147.291.901.901 (As at 31/12/2025: VND 144,658,924,552).

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

10. Construction in progress

	30/09/2026 VND	01/01/2026 VND
AQP assessment costs	-	1.277.777.778
Cost of research and development of pharmaceutical products	-	14.559.878.894
Lang Hoa Lac High-Tech Pharmaceutical Factory Project (*)	1.700.433.384	807.746.227.200
Total	**1.700.433.384**	**823.583.883.872**

(*) The Hataphar High-Tech Pharmaceutical Manufacturing Factory investment project is implemented according to Decision No. 163/QD-CNCHL dated October 07, 2020. The project covers an area of 45,188 m2 located at Lot CN1-03A-1, CN1-03A-2, CN1-03A-3, High-Tech Industrial Park 1, Hoa Lac High-Tech area, Thach That commune, Hanoi, with a total investment of VND 1,283 billion. The project includes the following main components: Office building and research center; Supercritical fluid extraction technology production factory; Hormone-containing drug production factory; Nanotechnology drug production factory; and Central warehouse. The project is divided into 4 phases, with the entire project expected to be fully operational in quarter 4/2027. Until the time prepare of this report, the project is in the infrastructure completion and handover phase.

11. Deferred expenses

	30/09/2026 VND	01/01/2026 VND
Long-term		
Tools and supplies	1.843.510.674	2.465.920.534
Cost of research and development of pharmaceutical products	11.663.916.776	-
Fixed asset repair expenses	4.459.983.625	2.858.499.091
Infrastructure rental expenses in the High-Tech Industrial Park	62.911.794.843	-
Others	6.710.512.062	307.754.625
Total	**87.589.717.980**	**5.632.174.250**

12. Trade accounts payable

	30/09/2026 VND		01/01/2026 VND	
	Amount	Amount able to be paid off	Amount	Amount able to be paid off
Short-term				
Quang Minh Medical and Pharmaceutical Company	564.299.713	564.299.713	564.299.713	564.299.713
Dong Au Trading and Production Co., Ltd	1.608.690.089	1.608.690.089	3.979.856.644	3.979.856.644
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	2.911.161.297	2.911.161.297	4.686.428.203	4.686.428.203
KPC Pharmaceuticals, Inc	23.564.450.840	23.564.450.840	19.025.983.320	19.025.983.320
XL Laboratories PVT.,LTD	-	-	22.359.757.441	22.359.757.441
Pharmaunity Co.,ltd	-	-	13.349.510.483	13.349.510.483
Delta Pharma Ltd	41.064.377.648	41.064.377.648	35.828.249.950	35.828.249.950
Blis pharma distribution and	40.993.472.156	40.993.472.156	40.758.864.060	40.758.864.060
Wockhardt Limited	27.379.879.924	27.379.879.924	10.056.600.528	10.056.600.528
Pharmametics products a division of max Biocare	28.523.500.250	28.523.500.250	13.799.528.479	13.799.528.479
Others	69.576.594.803	69.576.594.803	91.708.643.358	91.708.643.358
Total	**236.186.426.720**	**236.186.426.720**	**256.117.722.179**	**256.117.722.179**

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

13. Advances from customers

	30/09/2026 VND	01/01/2026 VND
Short term	**59,263,375,163**	**177,873,939,986**
In some of those transactions, the buyer's advance payments resulted in a large balance.		
T&T Equipment Joint Stock Company	2,449,398,000	790,000,000
T&T Pharmaceutical and Trading JSC	2,645,100,135	6,442,145,755
Thuan An Phat Pharmaceutical JSC	142,699,317	10,784,000,000
Dong Do Pharmaceutical Co., Ltd	-	2,502,291,750
TB Vietnam Pharmaceutical Trading Co., Ltd	4,751,201,723	49,761,555,583
Vietlife Pharmaceutical JSC	-	3,117,958,640
Hieu Anh Pharmaceutical Co., Ltd	8,350,000,000	8,045,259,000
Lam An Pharmaceutical Trading Co., Ltd	-	6,509,000,000
Life Pharmaceutical and Medical Equipment JSC	-	7,278,056,310
Dai Song Duong Pharmaceutical Co., Ltd	5,067,257,650	9,028,478,251
California USA Pharmaceutical Co., Ltd	3,348,673,410	5,753,424,645
French Pharmaceutical JSC	59,623,012	28,976,548,644
Others	32,449,421,916	38,885,221,408
Total	**59,263,375,163**	**177,873,939,986**

14. Taxes and payables to the State budget

Unit: VND

Items	01/01/2026	Amounts payable in the period	Amounts paid in the period	30/09/2026
Payables				
Value added tax for domestic goods	238,729,115	10,696,426,044	10,935,155,159	-
Value added tax for import goods	-	19,130,141,497	19,130,141,497	-
Import and export tax	-	978,988,525	978,988,525	-
Corporate income tax	3,932,013,924	8,648,826,234	10,586,737,553	1,994,102,605
Personal income tax	123,035,173	3,137,515,630	2,658,794,569	601,756,234
Natural resource tax	-	11,926,600	11,926,600	-
Land rental fee	-	2,116,532,582	2,116,532,582	-
Total	**4,293,778,212**	**44,720,357,112**	**46,418,276,485**	**2,595,858,839**

15. Accrued expenses

	30/09/2026 VND	01/01/2026 VND
Short-term		
Accrued interest expense	98,653,892	111,756,803
Accrued land rental expenses	1,200,000,000	-
Total	**1,298,653,892**	**111,756,803**

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

16. Deferred revenue

	30/09/2026 VND	01/01/2026 VND
Short-term		
Deferred revenue from leases	1.228.062.420	575.370.229
Total	**1.228.062.420**	**575.370.229**

17. Other payables

	30/09/2026 VND	01/01/2026 VND
a) Short-term	**1.133.800.665**	**191.526.944**
Others	1.133.800.665	191.526.944
b) Long-term	**3.196.200.000**	**3.337.100.000**
Deposits, collaterals	3.196.200.000	3.337.100.000
Total	**4.330.000.665**	**3.528.626.944**

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

18. Borrowings and finance lease liabilities

Unit: VND

	30/09/2026		In the period		01/01/2026	
	Amount	Amount able to be paid off	Increase	Decrease	Amount	Amount able to be paid off
a) Short-term Borrowings	**160.565.050.276**	**160.565.050.276**	**303.768.031.563**	**393.198.384.695**	**249.995.403.408**	**249.995.403.408**
a1) Short-term borrowing	***146.720.342.351***	***146.720.342.351***	***303.768.031.563***	***393.198.384.695***	***236.150.695.483***	***236.150.695.483***
Vietnam Joint Stock Commercial Bank for Industry and Trade - Thanh An Branch (1)	38.975.771.829	38.975.771.829	55.630.209.760	47.150.253.780	30.495.815.849	30.495.815.849
Joint Stock Commercial Bank For Foreign Trade Of Vietnam - West Hanoi Branch (2)	32.314.716.315	32.314.716.315	66.240.337.086	96.238.232.730	62.312.611.959	62.312.611.959
Shinhan Bank Vietnam Limited - Hanoi Branch (3)	28.620.229.843	28.620.229.843	84.961.274.419	108.391.905.565	52.050.860.989	52.050.860.989
Joint Stock Commercial Bank for Investment and Development of Vietnam - Ngoc Khanh Branch (4)	24.938.913.308	24.938.913.308	63.998.678.985	63.469.669.922	24.409.904.245	24.409.904.245
Vietnam Bank for Agriculture and Rural Development - Hanoi 2 Branch	-	-	21.118.721.175	41.952.072.044	20.833.350.869	20.833.350.869
Individuals (6)	21.870.711.056	21.870.711.056	11.818.810.138	35.996.250.654	46.048.151.572	46.048.151.572
a2) Long-term loans on due date	***13.844.707.925***	***13.844.707.925***	-	-	***13.844.707.925***	***13.844.707.925***
MUFG Bank, Ltd., - Hanoi City Branch (7)	13.844.707.925	13.844.707.925	-	-	13.844.707.925	13.844.707.925
b) Long-term borrowing	**83.068.247.547**	**83.068.247.547**	-	-	**83.068.247.547**	**83.068.247.547**
MUFG Bank, Ltd., - Hanoi City Branch (7)	83.068.247.547	83.068.247.547	-	-	83.068.247.547	83.068.247.547
Total	**243.633.297.823**	**243.633.297.823**	**303.768.031.563**	**393.198.384.695**	**333.063.650.955**	**333.063.650.955**

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

(1) Credit Contract No. 3110/2025-HDCVHM/NHCT320-HATAPHAR dated October 31, 2025, loan limit of VND 300 billion (including debts adjusted by Credit Contract No. 2209/2024-HDCVHM/NHCT320-HATAPHAR dated September 22, 2024), loan purpose: supplementing working capital for production and business activities; loan interest rate is the interest rate stated on each indebtedness certificate and is valid from the time of disbursement until the interest rate is adjusted; the loan term of each debt is stated on the indebtedness certificate but not exceeding 5 months/indebtedness certificate from the time of loan disbursement; Limit maintenance period until October 31, 2026; unsecured loan.

(2) Loan contract under the limit No. 15/26/QLN/HM/VCBTHN dated March 20, 2026 attached to the credit contract No. 15/26/QLN/CTD/VCBTHN dated March 20, 2026, the contract for issuing letters of credit under the limit No. 15/26/QLN/HMLC/VCBTHN dated March 20, 2026, the credit guarantee agreement under the limit No. 15/26/QLN/HMBL/VCBTHN dated March 20, 2026, the loan limit is VND 200 billion (including the limit of the loan contract under the limit No. 04/25/QLN/HM/VCBTHN dated February 02, 2025), the purpose of the loan is to finance short-term borrowing needs. legal, reasonable, valid to serve the production and business activities of the Customer but does not include short-term needs to serve fixed asset investment activities, interest rates are specifically regulated for each debt receipt; the loan term of each debt is a maximum of 05 months; the credit term is 12 months from the date of signing the contract or until April 12, 2027, whichever comes first; the loan is unsecured.

(3) Credit contract No. 130002065517 dated August 16, 2019 and extension - amendment supplement No. 130002065517/11 dated August 16, 2025 extending the limit until August 15, 2026, the loan limit is VND 80 billion, the purpose of the loan is to supplement working capital for production and business activities; loan interest rate: in case of fixed interest rate for the loan, the fixed interest rate is applied throughout the loan term according to the interest rate specified on the Drawdown Applications and Acknowledgement of Debt of each loan, in case of adjusted interest rate: apply the 3-month MFC reference interest rate plus (+) Margin of 0.74%/year and adjust every 3 months throughout the loan term; The term of each credit is within the limit specified in each indebtedness certificate but does not exceed 05 months/Acknowledgement of Debt; the loan is unsecured.

(4) Credit limit contract No. 01/2026/177578/HDTD dated June 18, 2026; regular credit limit with a maximum amount of VND 200 billion; loan purpose: supplementing working capital, guarantee, opening L/C; interest rate is determined in each specific contract according to the Bank's interest rate regime in each period; credit limit period is 12 months from the date of signing this Contract but not exceeding June 30, 2027; the loan is unsecured.

(5) Credit contract No. 1505-LAV-202500773 dated July 02, 2025 and Appendix No. 01 dated July 03, 2025, the loan limit is VND 30 billion, loan purpose and L/C payment: supplement working capital to support the company's production and business activities in 2025-2026; the loan interest rate will be a variable rate as stipulated by the bank at the time of loan disbursement; the loan term will be as specified in each debt acknowledgement but not exceeding 6 months; the credit limit will be granted for 12 months from the date of signing this contract; the loan is unsecured.

(6) Individuals loans according to each loan contract, for the purpose of serving the Company's production and business activities; loan term of less than 12 months; interest rate from 2%/year to 6.5%/year.

(7) Long-term Facility letter No. FL/053/22 dated August 02, 2022, Amendment agreement No. 02 dated January 17, 2023, Amendment agreement No. 03 dated December 27, 2023 of Long-term Facility Letter No. FL/053/22 dated August 02, 2022, the aggregate principal sum of the Facility shall not exceed VND 235 billion. The loan term until December 31, 2032, the Facility shall be used for Capital Expenditure/Factory Construction and for no other purpose. The specific interest rate for the first interest period in respect of an advance specified in a request for Advance which forms an inseparable part of such request shall be legally bound from the moment of the Customer and the Bank agree to such interest rate (whether orally or otherwise) and the request for Advance is deemed to have been accepted by the Bank from that moment thereof. The specific interest rate and other terms of the Advance shall be thereafter documented for evidentiary purposes in a notice (the "Advance") delivered by the Bank to the Customer. This loan is secured by the letter of guarantee issued by Aska Pharmaceutical Holdings Co., Ltd dated August 02, 2022. The first installment of each Advance shall be on the last Business day of December 2025, the subsequent installment shall be made every 12 months thereafter.

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

19. Owner's equity

a) Movement in owner's equity

Unit: VND

Items	Owner's contributed capital	Share premium	Other owner's capital	Treasury shares	Investment and development fund	Retained earnings	Total
Balance as at 01/01/2025	**823.417.730.000**	**96.320.000.000**	**24.375.893.101**	**(15.130.000)**	**8.963.148.976**	**64.536.134.228**	**1.017.597.776.305**
Profit in the previous year	-	-	-	-	-	52.445.587.221	**52.445.587.221**
Increase owner's equity from share premium	60.037.780.000	(60.037.780.000)	-	-	-	-	-
Increase owner's equity from retained earnings	22.300.000.000	-	-	-	-	(22.300.000.000)	-
Balance as at 31/12/2025	**905.755.510.000**	**36.282.220.000**	**24.375.893.101**	**(15.130.000)**	**8.963.148.976**	**94.681.721.449**	**1.070.043.363.526**
Profit in this period	-	-	-	-	-	26.125.077.825	**26.125.077.825**
Increase retained earnings from other owners' capital (*)	-	-	(24.375.893.101)	-	-	24.375.893.101	-
Balance as at 30/09/2026	**905.755.510.000**	**36.282.220.000**	**-**	**(15.130.000)**	**8.963.148.976**	**145.182.692.375**	**1.096.168.441.351**

(*) Increase "Retained earnings" from "Other owners' capital" according to Resolution No. 219/NQ-DHT dated March 30, 2026 of the Annual General Meeting of Shareholders of HaTay Pharmaceutical Joint Stock Company.

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

b) Details of owner's equity

	30/09/2026 VND	01/01/2026 VND
ASKA Pharmaceutical Co., Ltd	362.727.620.000	362.727.620.000
Mr Le Van Lo	50.819.900.000	50.819.900.000
Ms Le Viet Linh	57.441.840.000	57.441.840.000
Others	434.766.150.000	434.766.150.000
Total	**905.755.510.000**	**905.755.510.000**

c) Capital transactions with owners, dividend distribution and shared profit

	From 01/01/2026 to 30/09/2026 VND	From 01/01/2025 to 30/09/2025 VND
Owner's contributed capital		
Contribution at the beginning of the period	905.755.510.000	823.417.730.000
Increase in the period	-	-
Contribution at the end of period	905.755.510.000	823.417.730.000
Paid dividend, shared profit, bonus shares issued	-	-

d) Shares

	30/09/2026 Shares	01/01/2026 Shares
Number of shares registered for issue	90.575.551	90.575.551
Number of shares issued to the public	90.575.551	90.575.551
- Ordinary shares	*90.575.551*	*90.575.551*
Number of treasury shares	1.513	1.513
- Ordinary shares	*1.513*	*1.513*
Number of outstanding shares in circulation	90.574.038	90.574.038
- Ordinary shares	*90.574.038*	*90.574.038*

An ordinary share has par value of VND 10,000

e) Dividends

Dividends declared after the end of the accounting period:

- Dividends declared on ordinary shares: none
- Dividends declared on preferred stock: none

Unrecorded cumulative preferred stock dividends: none

20. Off Interim Separate Statement of Financial Position

Foreign currencies

	30/09/2026	01/01/2026
USD	18.676,25	4.387,44
EUR	357,85	365,98

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

II. Additional information for items presented in Separate Income Statement

1. Gross revenue from goods sold and services rendered

	Quarter III/2026	Quarter III/2025
	VND	VND
Revenue		
Sale of finished goods	119.956.153.614	124.183.370.114
Sales of merchandise	397.322.140.112	479.370.881.814
Total	**517.278.293.726**	**603.554.251.928**

2. Deductions

	Quarter III/2026	Quarter III/2025
	VND	VND
Sales return	283.302.244	15.697.260
Total	**283.302.244**	**15.697.260**

3. Net revenue from goods sold and services rendered

	Quarter III/2026	Quarter III/2025
	VND	VND
Net revenue		
Sale of finished goods	119.672.851.370	124.167.672.854
Sales of merchandise	397.322.140.112	479.370.881.814
Total	**516.994.991.482**	**603.538.554.668**

4. Cost of sales

	Quarter III/2026	Quarter III/2025
	VND	VND
Cost of finished goods sold	83.493.430.938	88.577.463.686
Cost of merchandise sold	389.419.454.526	471.663.523.339
Inventory handling costs	-	-
Total	**472.912.885.464**	**560.240.987.025**

5. Financial income

	Quarter III/2026	Quarter III/2025
	VND	VND
Financial income incurred in the period	3.226.139.139	10.554.757.527
Total	**3.226.139.139**	**10.554.757.527**

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

6. Financial expenses

	Quarter III/2026	Quarter III/2025
	VND	VND
Financial expenses incurred in the period	5.296.199.530	3.673.716.326
Total	**5.296.199.530**	**3.673.716.326**

7. Other income

	Quarter III/2026	Quarter III/2025
	VND	VND
Other income	15.858.648.657	4.181.387.197
Total	**15.858.648.657**	**4.181.387.197**

8. Other expenses

	Quarter III/2026	Quarter III/2025
	VND	VND
Other expenses	639.367.742	-
Total	**639.367.742**	**-**

9. Selling expenses and general administration expenses

	Quarter III/2026	Quarter III/2025
	VND	VND
a) Selling expenses incurred in the period	**7.193.907.168**	**6.580.717.254**
b) General administration expenses incurred in the period	**40.515.784.841**	**34.066.172.353**

10. Current corporate income tax expenses

	Quarter III/2026	Quarter III/2025
	VND	VND
Corporate income tax expense calculated on current taxable incomes	3.433.581.838	1.703.888.787

Approved, October 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by	Chief Accountant	General Director
Nguyen Hai Trieu	Dinh Nam Ha	Osamu Yomogida